J3 Vaccine Safety New Research Findings

Wednesday, March 30, 2011: 4:00 PM-5:00 PM
Presenters in this workshop will discuss new research findings related to vaccine safety including the risk of idiopathic thrombocytopenic purpura (ITP) after vaccination in children and adolescents and findings in the physical and metal functional status in persons who have received Anthrax vaccine.
Michael McNeil

4:00 PM
The Risk of Immune Thrombocytopenic Purpura After Vaccination In Children and Adolescents
Sean O'Leary, MD, Fellow, University of Colorado Denver; Jason Glanz, PhD; David McClure, PhD; Aysha Akhtar, MD, MPH; Matthew F. Daley, MD; Cynthia Nakasato, MD; Roger Baxter, MD; Robert Davis, MD, MPH; Hector Izurieta, MD, MPH; Tracy Lieu, MD, MPH; Robert Ball, MD, MPH
4:15 PM
Anthrax Vaccine Adsorbed (AVA) and SF-36v2 Physical and Mental Functional Status Scores In the Anthrax Vaccination Program (AVP)
Brock Stewart, PhD, Mathematical Statistician, CDC; Yujia Zhang, PhD; Charles Rose, PhD; Stacey W. Martin, MSc; Laura Franzke, PhD, MPH; Jerry Tokars, MD, MPH; Michael Mcneil, MD, MPH
4:30 PM
What Healthcare Providers Need to Know about the Vaccine Adverse Event Reporting System (VAERS) Reporting and Public Health Uses
Elaine R. Miller, RN, MPH, Epidemiologist, Centers for Disease Control and Prevention; Beth Hibbs, RN, MPH, Nurse Consultant, Centers for Disease Control and Prevention; Pedro Moro, MD, MPH; Kamesha Smith, MPH; Pamela Bryant, MS; Karen Broder, MD
4:45 PM
Postlicensure Safety Monitoring of Quadrivalent Human Papillomavirus Vaccine (HPV4)
Julianne Gee, MPH, Epidemiologist, Centers for Disease Control and Prevention; Barbara Slade, MD, MS; Karen Broder, MD; Claudia Vellozzi, MD, MPH
See more of: Submissions